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Edited by Lukas Hu¨berAbstract Cardiac diﬀerentiation involves cross-regulation of
several transcription factors, such as Mef2C, regulated by
p38a MAP kinase. We analysed the role of p38a in cardiac dif-
ferentiation. Either the absence or inhibition of p38a impairs
MEF2C nuclear localization in cardiomyocytes, colocalising
with vimentin at the perinuclear region. As a consequence,
expression of the Mef2C targets, ANF and myocardin, is drasti-
cally downregulated. In contrast, Mlc2v and crt are mainly unal-
tered, probably by the strong Mef2B upregulation, conpensating
for the impaired Mef2C transactivity. In addition, p38a deﬁ-
ciency leads to a decrease in the phosphorylated Mlc2v fraction
and a-actinin accumulation causing sarcomere disorganisation.
We propose a critical role for p38a in early stages of cardiac dif-
ferentiation by modulation of Mef2C localisation and sarcomeric
assembly.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The molecular basis of cardiac diﬀerentiation during heart
morphogenesis, a complex cellular process that comprises cell
proliferation, migration and diﬀerentiation is not so well under-
stood [1,2]. The MADS-box family of transcriptional regula-
tors, myocyte enhancer factor-2 (MEF-2) proteins, have been
widely implicated in cardiomyocyte maturation and diﬀerenti-
ation [2–4]. The ﬁrst Mef2 family members to be expressed dur-
ing mouse cardiac development are Mef2B and Mef2C, while
Mef2A and Mef2D are later expressed [5]. Data from homozy-
gous Mef2C knockout mouse embryos and conditional Mef2-
CloxP/loxP mice demonstrate an essential role for Mef2C only
in early stages of cardiac diﬀerentiation, possibly due to func-
tional redundancy by Mef2A in later stages [4–6]. Regulation
of Mef2 function is complex, including protein–protein interac-
tions with other transcription factors and/or transcriptional*Corresponding authors. Fax: +34 953 211875 (F. Navarro), +34 953
211875 (A.E. Ara´nega).
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doi:10.1016/j.febslet.2008.02.050regulators, phosphorylation by cyclin-dependent kinases, inter-
actions with histone deacetylases, control by Ca2+-dependent
signalling cascade and interaction and phosphorylation by
mitogen-activated protein kinases (MAPK) [7–9].
p38 MAPKs were originally shown to be activated in re-
sponse to stress and proinﬂammatory cytokines, but non-
stressful stimuli also activate them [10]. Four diﬀerent p38
MAPKs isoforms have been identiﬁed: p38a, b, c, and d, which
may have both overlapping and speciﬁc functions [10]. p38a is
widely expressed and is the most abundant p38 family member.
Loss of p38a has been established to cause embryonic lethality
at midgestation due to a placental defect [11,12]. Diﬀerent evi-
dences point out to a crucial role for p38 MAPKs in the regu-
lation of Mef2 transcriptional activity during mammalian
somite development and myotome formation, as well as in skel-
etal muscle diﬀerentiation [13]. Furthermore, p38a has been re-
ported to physically interact with Mef2C leading to its
phosphorylation, which in term regulates its transactivation
activity [14]. Similarly Mef2A is a substrate for p38a [15]. Some
evidences indicate the involvement of the p38 MAPK pathway
and some of their regulators, such as Rac1, in cardiac diﬀeren-
tiation [16]. In addition, p38 MAPKs play an important role in
the regulation of cardiomyocyte proliferation, hypertrophy,
apoptosis and growth response [10,17,18], although the precise
role of this MAPK in cardiogenesis remains unclear.
We report here, that p38a plays a critical role in early stages
of cardiac cell diﬀerentiation through an operative p38a/Mef2C
pathway. Lack or inhibition of p38a results in Mef2C misloca-
tion, which prevents nuclear localization, probably through
blockage of p38a-mediated Mef2C phosphorylation. This cor-
relates with a decrease in the expression of some cardiac Mef2C
targets, such as the atrial natriuretic factor, ANF, and myocar-
din. In contrast, expression of other Mef2C targets is not al-
tered, probably through compensation mediated by the
upregulation of Mef2B expression. In addition, p38a regulates
sarcomeric assembly through regulation of ventricular myosin
light chain 2 (mlc2v) phosphorylation and insertion into sarco-
meric units, as well as the accumulation of a-actinin.2. Materials and methods
2.1. Cell lines and culture conditions
p38a/ and wild-type embryonic cardiomyocytes were isolated
from E 9.5 embryos obtained by intercrossing mice heterozygous
for p38a and those carrying large T antigen under the control of ablished by Elsevier B.V. All rights reserved.
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transgene) [19]. Cardiomyocytes were isolated as previously described
[12] and were grown on collagen-coated tissue culture plates in DMEM
containing 10% fetal bovine serum (Invitrogen), IFN-c (10 U/ml; SIG-
MA), and cardiotrophin-1 (0.2 ng/ml; R&D Systems, Minneapolis,
MN) at 33 C in humidiﬁed atmosphere of 5% CO2.
p38 inhibitor, SB203580, was dissolved in DMSO and added directly
to the culture medium to a ﬁnal concentration of 2.5 lM. Cells were
incubated in the presence of the inhibitor for up to 48 h.
2.2. mRNA extraction and reverse transcription
Total RNA was extracted from mouse p38a/ and wild-type
cardiomyocytes, using the eukaryotic Perfect RNA mini-kit (Eppen-
dorf) according to the manufacturers guidelines. Genomic DNA was
removed by treatment with RNase-free DNase (Roche) for 1 h at
30 C. First-strand cDNA was synthesized using 1 lg of RNA, oli-
go-dT primers and Superscript RNase H reverse transcriptase (Invit-
rogen) (37 C for 1 h), following manufacturers protocol. As a
negative control for genomic DNA contamination, each sample was
subjected to the same reaction without reverse transcriptase.
2.3. Quantitative real time PCR (Q-PCR)
Real-time PCR was performed within an iCycler PCR thermocycler
(Bio-Rad, Spain) and SYBR Green detection system (Bio-Rad). Reac-
tions were performed in 96-well plates with optical sealing tape (Bio-
Rad) in 20 ll total volume containing cDNA corresponding to
150 ng of total RNA. Mouse b-actin was used as internal control
[20]. Each PCR reaction was performed at least ﬁve times to obtain
a representative average. The relative level of expression of each gene
was calculated as the ratio of the extrapolated levels of its expression
and b-actin mRNAs. The ampliﬁcation PCR products were analysed
in agarose gel electrophoresis.Sequence
GATA-4 501 CCGAGGGTGAGCCTGT
301 CCGAGGGTGAGCCTGT
GATA-5 501 GTCAACCGACCGCTAG
302 CATTGCCAGTGGCCTT
GATA-6 501 AGTGGCTCTGTCCCTA
302 GGATGTGACTTCGGCA
Mef2A 501 GTAGCGGAGACTCGGA
301 ATCTTCTTTCGCCCCA
Mef2B 501 CTGGAGAGAAGCTGCT
301 CAAGGTGGCTTGGAGA
Mef2C 503 AGAAGAAACACGGGGA
303 GGGGTGAGTGCATAAG
Mef2D 501 CAGCAGCCAGCACTAC
301 ACTTGGCAGGGATGAC
Mlc2v 501 TGTTCCTCACGATGTT
301 CTCAGTCCTTCTCTTC
aMHC 501 CTCAGCCAGGCCAATA
302 GACTCCATCTTCTTCT
bMHC 501 AGATCGCCCTCAAGGG
301 AGGTCCTGGAGCCGCA
CRT 501 AGGCTCCTTGGAGGAT
301 TCCCACTCTCCATCCA
ANF 503 CCTGTGTACAGTGCGG
303 TCTCAGAGGTGGGTTG
Myocardin 501 ATGCAGTGAAGCAGCA
301 AAGATGCCTGCTCAAA
b-Actin +374F TGAGGAGCACCCTGTG
517R CCAGAGGCATACAGGGThe primers used were as follows (all 5 0–3 0):
2.4. Immunocytochemistry
Wild-type and p38a/ cardiomyocytes cell lines were grown on
collagen-coated cover slides. Cells were washed in PBS twice for
5 min and were ﬁxed for 20 min in 4% paraformaldehyde at room
temperature and hydrated through graded ethanol steps. Cells were
brieﬂy rinsed in PBS and blocked at room temperature using
TBSA-BSAT (10 mM Tris, 0.9% NaCl, 0.02% sodium azide, 2% bo-
vine serum albumin and 0.1% Triton-X100). Rehydrated cells were
incubated overnight at room temperature with primary antibodies
at 1:200 (anti-vimentin), 1:100 (a-actinin, MLC2v) and 1:50 (Mef2c
and Gata4). Gata4 goat polyclonal, Mef2c goat polyclonal rabbit
polyclonal antibodies were purchased from Santa Cruz Biotechnol-
ogy Inc. The rabbit polyclonal antibody recognizing a-actinin and
the monoclonal for anti-vimentin were purchased from Sigma. The
MLC2v monoclonal antibody was kindly provided by W. Franz Lu¨-
beck, Germany.
After rising, cells were incubated for 5 h with antirabbit, antigoat
or anti mouse Cy3 secondary antibodies (Jackson Labs, USA) di-
luted in TBSA-BSAT (1:100). Nuclear staining was performed using
DRAQ-5 (red Fluorescen Cell-Permeable DNA probe, Biostatus
Limited, United Kingdom). Immunoﬂuorescence analysis was car-
ried out in a leica TCS SL confocal microscope (Leica LCS Version
2.0).
2.5. Western blot analysis
Western blot analysis was carried out as previously described using
total cell protein extracts [12]. The rabbit polyclonal antibody recogn-
ising phosphorylated MLC2v, muRLCP, was kindly provided by
Dr. N.D. Epstein, USA [21]. To normalize an anti-tubulin antibody
(Sigma T5168) was used.Size of cDNA ampliﬁcation (bp)
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Fig. 1. Expression levels and localisation of cardiac transcription
factors is not compromised in the absence of p38a MAPK. Quanti-
tative RT-PCR analysis of mRNA expression levels for GATA4,
GATA5, GATA6 and Mef2C (A) and immunolocalisation of GATA4
transcription factor (B) in wild-type (p38) and p38a/ cardiomyocytes
(p38/).
Fig. 2. p38a MAPK deﬁciency or inhibition alters localisation of
Mef2C. (A) Immunolocalisation of Mef2C showing its mislocation in
the cytosol in p38a/ (p38a/) as compared with wild-type
cardiomyocytes (p38a). (B) Co-immunolocalisation of Mef2C and
vimentin in the perinuclear region in p38a/ cardiomyocytes. (C)
Inhibition of p38a MAPK with SB203580 (2.5 lM) for 24 or 48 h,
impairs Mef2C nuclear translocation in wt cardiomyocytes.
DRAQ5TM (in blue) localises in the nucleus.
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3.1. Cardiac transcription factors expression is not dependent on
p38a MAPK
To explore the involvement of p38aMAPK in cardiac diﬀer-
entiation, we used immortalized mouse wild-type and p38a/
cardiomyocytes from E9.5 embryos. mRNA expression levels
for GATA4, GATA5 and GATA6 transcription factors,
known to be expressed at early stages of cardiac diﬀerentiation
[1], as well as Mef2C, the most important member of Mef2
family shown to play a role in early heart formation [5], were
analysed by quantitative real time PCR. As shown in Fig. 1A,
mRNA levels were similar in both wild-type and p38a/
cardiomyocytes, indicating that gene expression of these tran-
scription factors is independent of p38a MAPK in these
cardiomyocytes cell lines.
In addition, we performed immunohistochemistry experi-
ments to compare the localisation of GATA4 in wild-type
and p38a/ cardiomyocytes. As expected, GATA4 was local-
ised in the nucleus of wild-type cardiomyocytes and no signif-
icant diﬀerences were found in p38a/ cell line (Fig. 1B).
Similar results were obtained for Nkx2.5 (not shown).
3.2. Nuclear Mef2C localisation is compromised in the absence
of p38a MAPK
Phosphorylation of Mef2C by p38a MAPK regulates its
transactivation activity [7]. To determine whether nuclear
localisation of Mef2C could be impaired or altered in the ab-
sence of p38a, immunolocalisation of Mef2C was analysed in
immortalised wild-type and p38a/ cardiomyocytes. Fig. 2A
illustrates the intranuclear localisation of Mef2C in cultured
wild-type cardiomyocytes. In contrast, in p38a/ cardiomyo-
cytes Mef2C nuclear translocation was mainly impaired
(Fig. 2A) remaining in the perinuclear region colocalising with
vimentin (Fig. 2B), a component of intermediate ﬁlament (IF)[22]. Thus, in contrast to other cardiac transcription factors,
which do not appear to be regulated by p38a, Mef2C nuclear
localisation seems to be p38a MAPK dependent.
To demonstrate that Mef2C mislocation observed in
p38a/ cardiomyocytes was dependent on p38a activation,
wild-type cardiomyocytes were treated with the speciﬁc p38
inhibitor SB203580 and Mef2C localization was analyzed.
Treatment with low doses of SB203580 for 24 h led to a defect
in Mef2C nuclear accumulation and Mef2C was mainly in the
perinuclear region. This eﬀect was stronger after 48 h treat-
ment, clearly aﬀecting Mef2C translocation into the nucleus
(Fig. 2C). These results conﬁrm those from p38a/ cardio-
myocytes, demonstrating that Mef2C nuclear translocation
in cardiomyocytes is dependent on p38a activity.
Fig. 3. Analysis of the expression of Mef2C targets and Mef2 family
members. Quantitative RT-PCR analysis of mRNA levels for the
Mef2C targets ANF, myocardin, crt and mlc2v (A) and Mef2A,
Mef2B, and Mef2D (B) in wild-type (p38) and p38a/ cardiomyocytes
(p38/).
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that Mef2C would be functionally inactive in p38a/ cardio-
myocytes. Thus, we analysed the expression of Mef2C gene
targets ANF, myocardin, calreticulin (crt) and Mlc2v, markers
of cardiac diﬀerentiation [23–26], by quantitative RT-PCR
in wild-type and p38a/ cardiomyocytes. As expected
(Fig. 3A), in the absence of p38a MAPK ANF and myocardin
drastically decreased. However, crt and Mlc2v mRNA levels
were not signiﬁcantly modiﬁed by p38a deﬁciency (Fig. 3A).
This might be a consequence of a compensation exerted by
other Mef2 family members, Mef2A, -B and -D, which are also
involved in cardiac diﬀerentiation and could replace Mef2C, as
it has been previously shown [5]. To analyse this possibility
Mef2A, Mef2B and Mef2D mRNA levels were analysed by
QRT-PCR. In p38a/ cardiomyocytes, Mef2B expression
was about sixfold higher than in wild-type cardiomyocytes
(Fig. 3B). In contrast, Mef2A expression highly decreased un-
der p38a deﬁciency (about 80%), while Mef2D mRNA expres-
sion was similar in both cardiomyocytes cell lines. Our results
suggest that the increase in Mef2B expression could compen-
sate Mef2C transcriptional activity deﬁciency and are in line
with those previously reported by Lin and co-workers demon-
strating that in Mef2C/ mice embryos, Mef2B was up-regu-
lated by more than sevenfold, probably partially replacing
MEF2C [5].
3.3. Cardiomyocytes sarcomeric organisation is altered in the
absence of p38a MAPK
A hallmark of diﬀerentiated myocardial cells is the forma-
tion and organisation of sarcomeres. Thus, we studied the for-
mation of organised sarcomeres.
We analysed, by QRT-PCR, in wild-type and p38a/
cardiomyocytes, the expression of myosin heavy chain a-
MHC and b-MHC, which are constitutive contractile proteins.
The analysis shows that a-MHC and b-MHC mRNA expres-
sion was not mainly aﬀected (Fig. 4A), as it was observedfor Mlc2v, indicating that p38a does not regulate mRNA
expression of contractile proteins. Then, Mlc2v and a-actinin
protein expression as well as their incorporation into the sarco-
meric units was evaluated by immunoﬂuorescence. In wild-
type cardiomyocytes, a-actinin and Mlc2v appeared organised
into nascent sarcomeric units (Fig. 4B), indicating that cardiac
sarcomeres formation normally occurs in these immortalised
cardiomyocytes. However, p38a/ myocardial cells showed
low levels and anomalous distribution of both a-actinin and
Mlc2v proteins, suggesting that sarcomere formation, and as
a consequence, diﬀerentiation of cardiomyocytes is dependent
on p38a MAPK. In contrast, localisation of a-MHC and b-
MHC proteins in these cells was not altered (data not shown).
Treatment of wild-type cardiomyocytes with SB203580 for
48 h, dramatically decreased Mlc2v and a-actinin protein accu-
mulation as it happens in p38a/ cells (Fig. 4C), leading to a
disorganisation of sarcomeric units.
Phosphorylation of Mlc2v by Myosin light chain kinase
(MLCK) is required for its assembly into sarcomeres in cardio-
myocytes [27]. Unphosphorylated Mlc2v is unable to assemble
into the sarcomere, leading to a disorganisation of sarcomeres
in ES-derived cardiomyocytes [28]. Thus, p38a MAPK might
play a role in MLC2v phosphorylation. This was studied by
Western blot analysis using a monoclonal antibody against
phosphorylated MLC2v [21]. As shown in Fig. 4D, phosphor-
ylation of MLC2v highly decreased (by 80%) in p38a/
cardiomyocytes as compared with wild-type cells.
All these results demonstrate that both, sarcomeric organisa-
tion and MLC2v phosphorylation are dependent on p38a
MAPK in cardiomyocytes. Thus, in the absence of p38a,
MLC2v failed to incorporate into the sarcomere, being distrib-
uted in the cytosol as short disorganised ﬁlaments.4. Discussion
p38 MAPKs have been implicated in the regulation of car-
diomyocyte proliferation, hypertrophy, apoptosis and growth
response [17]. However, the involvement of speciﬁc p38 MAP-
Ks isoforms in cardiogenesis is still largely unknown.
Our results demonstrate a dual role for a speciﬁc p38 MAPK
isoform, p38a, in early stages of cardiac cell diﬀerentiation.
This dual role implies the existence of an operative p38a/
Mef2C pathway where p38a modulates the localisation of
Mef2C, which shuttles between the nucleus and the cytoplasm.
p38a mediated Mef2C phosphorylation would be a prerequi-
site for Mef2C nuclear localisation. Therefore, upon p38a inhi-
bition it remains localised at the perinuclear region. In
addition, p38a modulates sarcomeric organisation by regulat-
ing Mlc2v phosphorylation and a-actinin accumulation. Ab-
sence or inhibition of p38a leads to a high decrease in Mlc2v
phosphorylation and a-actinin levels, resulting in disorganised
sarcomere units.
p38a can physically interact with Mef2C, promoting its
phosphorylation, which leads to the regulation of its transacti-
vating activity in the nucleus [14,15]. Our results demonstrate
that Mef2C nuclear translocation would be primarily depen-
dent on p38a-mediated Mef2C phosphorylation as an essential
initial step. This is supported by our immunolocalisation data
demonstrating that Mef2C nuclear translocation is impaired
by p38a deﬁciency or inhibition, leading to a perinuclear distri-
bution and a co-localization with vimentin [22]. During cardi-
Fig. 4. Analysis of structural and sarcomeric proteins. (A) Quantitative RT-PCR analysis showing no signiﬁcant diﬀerences between wild-type (p38,
squared bar) and p38a/ cardiomyocytes (p38/, dotted bar) in mRNA expression for alfa-MHC and beta-myosin. (B) Immunolocalisation of
mlc2v and a-actinin, demonstrate a sarcomeric disorganisation in p38a/ (p38a/) as compared with wt cardiomyocytes (p38a). (C) Inhibition of
p38a MAPK with SB203580 (SB) for 48 h impairs proper mlc2v incorporation into the sarcomeres, decreases a-actinin accumulation and
disorganises the sarcomeres in wt cardiomyocytes. DRAQ5TM (in blue) localises in the nucleus. (D) Western blot analysis of phosphorylated Mlc2v
(Mlc2v-p) shows a dramatic decrease in p38a/ cardiomyocytes (p38a/). a-Tubulin was used as a loading control.
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also established as a Ca2+ dependent process involving calret-
iculin and CaN [28,29]. A cross-talk between p38 MAPK and
Ca2+ pathways has been previously proposed [9]. However, we
cannot exclude the possibility of the existence of two indepen-
dent pathways, the p38 MAPK and the Ca2+-dependent path-
way, which would regulate Mef2C activity and localisation.
According to this, calreticulin, a Mef2C gene target, involved
in the regulation of Mef2C nuclear localisation and activity
[28], is not altered in p38a/ cardiomyocytes, suggesting the
presence of a correct supply of Ca2+ within the cell [24].
Mef2C is a transcription factor expressed early (at E7.5 in
mice) during heart development in vertebrates, whose genetic
ablation causes morphological and transcriptional abnormali-
ties during early cardiogenesis [4]. A cooperative interaction
between Mef2C and other cardiac transcription factors o tran-
scriptional co-activators is essential for synergistic activation
of diﬀerent cardiac promoters, such as ANF by Mef2C and
dHAND, or myocardin by cooperation between myocardin
and Mef2C, allowing the correct initiation of the cardiac diﬀer-
entiation program [2,3,23,26,30,31]. According to this, inp38a/ cardiomyocytes, ANF and myocardin expression
drastically decrease probably as a consequence of the defect
in Mef2C function. These results point out to the alteration
of the cardiac diﬀerentiation program by disruption of the
p38a/Mef2C pathway, which agrees with previous data ob-
tained in neonatal rat ventricular cardiomyocytes maintained
in culture, P19 cells and transgenic mice and demonstrate an
essential role for Mef2 in the maintenance and diﬀerentiation
of cardiomyoblast, probably by the existence of a positive reg-
ulatory loop between Mef2C, Nkx2.5 and GATA4 [3,18].
Surprisingly, as it is the case for crt, we found no signiﬁcant
diﬀerences in the expression of the Mef2C gene target Mlc2v
[24] in p38a/ cardiomyocytes. This might be a consequence
of the upregulation of Mef2B expression, which probably com-
pensates for the lack of Mef2C activity. In contrast, Mef2A
expression drastically decreases in p38a/ cardiomyocytes
andMef2D levels were similar in both cell lines. Interestingly, it
has been demonstrated that p38a phosphorylates Mef2A, but
not Mef2B and Mef2D [15]. In line with our results, a redun-
dancy between MEF2C and other family members in heart
development has been reported in hearts from conditional
Fig. 5. A model of p38a-Mef2C pathway and sarcomeric organisation
during early stages of cardiac diﬀerentiation. The model shown p38a
pathway regulating Mef2C phosphorylation as a prerequisite for its
translocation into the nucleus. Proper Mef2C nuclear translocation is
necessary to its cooperation with cardiac transcription factors and
regulation of diﬀerent target genes for proper activation of cardiac
diﬀerentiation program during early stages of the development. p38a
also regulates Mef2A phosphorylation. Activation of MAPKAPK-2
by p38a allows phosphorylation of MLCK, and then, phosphorylation
of Mlc2v prior to its incorporation into the sarcomeric units.
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was proposed to be involved in the induction of Mlc2v expres-
sion [5]. All these results suggest that p38a MAPK is required
for proper and speciﬁc activity of Mef2C and Mef2A and point
to the existence of diﬀerent mechanisms controlling the expres-
sion and activity of the four Mef2 members throughout diﬀer-
entiation.
In addition, our results demonstrate that p38a deﬁciency
does not alter either mRNA expression or nuclear localisation
of other cardiac transcription factors such as GATA4,
GATA5, GATA6 and Nkx2.5 known to play a pivotal role
in early cardiogenesis [1,31]. These results agree with those pre-
viously reported in crt/ mice and cultured crt/ cardiomyo-
cytes, where Mef2C mislocation in the cytosol does not alter
the expression or localisation of GATAs and Nkx2.5 [28].
Sarcomere formation implies the phosphorylation of Mlc2v
by MLCK and its insertion into sarcomeric units [27]. Our re-
sults demonstrate a p38a-dependent MLC2v phosphorylation,
therefore p38a deﬁciency results in a low amount of phosphor-
ylated Mlc2v. Moreover, p38a deﬁciency or inhibition results
in a cytosolic distribution of Mlc2v as short disorganised ﬁla-
ments and a decrease in the levels of the sarcomeric protein a-
actinin, leading to defects in myoﬁbrillogenesis. In vitro, MAP
kinase-activated protein kinase 2 (MPAKAPK-2), a substrate
of p38a and p38b, phosphorylates MLCK [32]. In addition,
activation of MAPKAPK-2 is completely inhibited in rat heart
by the p38 inhibitor SB203580 [33], totally impaired in p38a/
cardiomyocytes [12] and inactive in p38a/ ES cells [34].
Then, it is likely that a p38a/MPAKAPK-2/MLCK cascade
can be functioning in cardiomyocytes, allowing phosphoryla-
tion of Mlc2v prior to its assembly into sarcomeric units.
Our results also agree with those showing that in Mef2C/
cardiomyocytes and ES derived-cardiomyocytes expressing a
dominant negative form of Rac1, an upstream p38a MAPK
activator, myoﬁbrillogenesis is altered, accompanied by com-
promised cardiac cell diﬀerentiation [4,16].
Taking together, our results point out to a role of p38a
MAPK in early cardiac diﬀerentiation and are in agreement
with Aouadi et al. [35], who demonstrated that p38 activation
or inhibition constitutes a switch between cardiomyogenesis
and neurogenesis, respectively. They are also in agreement
with data demonstrating a role for p38 in mouse lung stem
and progenitor cells diﬀerentiation [36]. Based on previous
data and our own results, we propose the scheme shown in
Fig. 5, illustrating the connection between p38a MAPK path-
way, Mef2C and sarcomere organisation. In cardiomyocytes,
p38a mediates Mef2C phosphorylation as a prerequisite to
its translocation into the nucleus. Then, cooperation with
other cardiac transcription factors regulates diﬀerent target
genes allowing proper activation of cardiac diﬀerentiation pro-
gram during early stages of development. Activation of MAP-
KAPK-2 by p38a would allow phosphorylation of MLCK,
and then that of Mlc2v as well as its incorporation into sarco-
meric units.
Future studies would be necessary to fully analyse the pre-
cise role played by p38a and other p38 MAPKs isoforms as
well as the connection with the Mef2 family members in the
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